Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407650 | 0.85 | POLB (0.39) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL23675586 | 0.82 | NPC1 (0.34) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL19818391 | 0.82 | NPC1 (0.34) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL9967682 | 0.78 | CHRM2 (0.37) | NPC1RAB9AALOX5 | |
| SCHEMBL12394760 | 0.77 | ALOX5 (0.35) | ALOX5 | |
| SCHEMBL104309 | 0.76 | CHRM2 (0.50) | NPC1RAB9APOLBL3MBTL1ALOX5 | |
| SCHEMBL8224692 | 0.76 | CYP2A6 (0.42) | ALOX5 | |
| SCHEMBL17929805 | 0.76 | ALOX5 (0.30) | ALOX5 | |
| SCHEMBL459430 | 0.76 | CHRM2 (0.36) | NPC1RAB9APOLBL3MBTL1GABRA1 | |
| SCHEMBL9967681 | 0.76 | ALDH1A1 (0.43) | NPC1RAB9APOLBL3MBTL1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-20170073511-A1 | METHOD FOR MAKING HETEROPHASIC POLYMER COMPOSITIONS | MILLIKEN & COMPANY | 2017-03-16 | — | — | US | disclosed |
| US-20170073511-A1 | METHOD FOR MAKING HETEROPHASIC POLYMER COMPOSITIONS | MILLIKEN & COMPANY | 2017-03-16 | — | — | US | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-9410035-B2 | Modified heterophasic polyolefin composition | MILLIKEN & COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160024289-A1 | MODIFIED HETEROPHASIC POLYOLEFIN COMPOSITION | MILLIKEN & COMPANY | 2016-01-28 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | NPC1 4487/4885RAB9A 2628/4885POLB 3356/4885 |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | BTK, SYK, LYN | NPC1 3303/4885RAB9A 2603/4885POLB 2697/4885 |
| US-10012650-B2 | Assays for BTK inhibitors | BTK, SYK, LYN | NPC1 3303/4885RAB9A 2603/4885POLB 2697/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | NPC1 1389/4885RAB9A 1576/4885POLB 300/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | NPC1 4487/4885RAB9A 2628/4885POLB 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.